Is BioNTech SE (BNTX) A Good Stock To Buy Now?

We came crossed a bullish thesis connected BioNTech SE connected Memyselfandi007’s Substack. In this article, we volition summarize the bulls’ thesis connected BNTX. BioNTech SE's stock was trading astatine $103.80 arsenic of March 4th. BNTX’s trailing and guardant P/E were 166.87 and 7.04 respectively according to Yahoo Finance.

Photo by National Cancer Institute connected Unsplash

BioNTech SE (BNTX) has transitioned from a COVID-19 vaccine pioneer to a diversified biotech institution with a increasing absorption connected oncology, positioning itself for imaginable upside contempt near-term uncertainties. After its archetypal occurrence with the mRNA COVID vaccine successful concern with Pfizer, BioNTech has expanded its exertion level done strategical acquisitions, including the acquisition of Chinese startup Biotheseus.

This acquisition rapidly yielded a landmark woody with Bristol Myers for BNT327, generating $2 cardinal successful upfront payments positive a 50% royalty share, highlighting BioNTech’s quality to capitalize connected high-value pipeline opportunities. Financially, the institution enters 2026 with a robust €17.2 cardinal currency presumption against a marketplace capitalization of ~€22 billion, providing a beardown buffer for ongoing R&D and strategical initiatives.

Operationally, BioNTech has remained currency travel affirmative successful 2025, driven by BNT327 milestones and residual COVID vaccine sales, portion its GAAP losses proceed to narrow. AI-driven analyses of the oncology pipeline suggest a risk-adjusted nett contiguous worth (rNPV) of €7–8 cardinal successful a basal case, implying a full equity worth including currency of €24–25 billion, with a bull lawsuit reaching €32 cardinal if pipeline programs succeed.

Despite uncertainties astir regulatory hurdles, competition, and manufacturing complexity, the marketplace presently underprices the imaginable of BioNTech’s pipeline, creating a favorable risk/reward profile.

With experienced management, proven deal-making ability, and a diversified improvement pipeline, BioNTech represents a compelling accidental for investors seeking vulnerability to innovation-driven maturation successful the biotechnology sector, wherever palmy objective readouts could unlock important upside. Even blimpish estimates suggest that the banal trades beneath its intrinsic value, making it an charismatic bargain for those consenting to navigate biotech execution risk.

Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted upside from emerging infectious illness risks, organization accumulation, method signals, and options flow. MRNA’s banal terms has appreciated by astir 73.67% since our coverage. Memyselfandi007 shares a akin presumption but emphasizes BioNTech SE’s (BNTX) diversification into oncology, strategical deals similar BNT327 with Bristol Myers, and a beardown currency presumption supporting its pipeline value.